A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

Research Site, Belgium

Research Site, Darlinghurst

Research Site, Leuven

Research Site, East Melbourne

Research Site, Herston

Research Site, Woolloongabba

Research Site, Bruges

Research Site, Ghent

Research Site, Candiolo

Research Site, Berlin

Research Site, Marseille

Research Site, Schwerin

Research Site, Milan

Research Site, Lutherville-Timonium

Research Site, Buxtehude

Research Site, Kiel

Research Site, Madrid

Research Site, Madrid

Research Site, Madrid

Research Site, Madrid

Research Site, Pozuelo de Alarcón

Research Site, Málaga

Research Site, Pamplona

Research Site, Tampa

Research Site, Padua

Research Site, Nashville

Research Site, Siena

Research Site, Vandœuvre-lès-Nancy

Research Site, Mainz

Research Site, Pau

Research Site, Heidelberg

Research Site, Pierre-Bénite

Research Site, Heilbronn

Research Site, Paris

Research Site, Napoli

Research Site, München

Research Site, Poitiers

Research Site, Los Angeles

Research Site, Boulogne-Billancourt

Research Site, Bobigny

Research Site, Regensburg

Research Site, San Francisco

Research Site, Villejuif

Research Site, Sacramento

Research Site, Edmonton

Research Site, Toronto

Research Site, Toronto

Research Site, Ste-Foy

Research Site, Tübingen

Research Site, Perugia

Research Site, Roma

Research Site, Brzozów

Research Site, Gdansk

Research Site, Krakow

Research Site, Lodz

Research Site, Poznan

Research Site, Warsaw

Research Site, Goyang

Research Site, Seoul

Research Site, Seoul

Research Site, Seoul

Research Site, Barcelona

Research Site, Cambridge

Research Site, Chelsea

Research Site, Manchester

Research Site, Northwood